GPC
PCRX icon

Glacier Peak Capital’s Pacira BioSciences PCRX Stock Holding History

Glacier Peak Capital’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-6,250
Closed -$442K – 64
2015
Q2 		$442K Buy
+6,250
New +$492K 0.22% 61

Other funds holding PCRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
MCM
Marsico Capital Management Denver, Colorado $3.83B AUM 63.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
HCM
Hoplite Capital Management New York $15.1M AUM 27.41% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Glacier Peak Capital's PCRX Position: Q3 2015 in Review

Glacier Peak Capital sold out of Pacira BioSciences (PCRX) in Q3 2015, closing a stake of 6,250 shares — an estimated $442K sold.

Glacier Peak Capital first reported a position in PCRX in Q2 2015 and held it in 1 quarter. The position peaked at $442K in Q2 2015. 177 funds tracked by Wall St. Rank hold PCRX as of Q3 2015.

  • Glacier Peak Capital reported no remaining Pacira BioSciences position as of Q3 2015 after selling out during the quarter.
  • Glacier Peak Capital sold 6,250 Pacira BioSciences shares in Q3 2015, an estimated $442K.
  • Glacier Peak Capital first reported a position in Pacira BioSciences in Q2 2015 and held it in 1 quarter.
  • Glacier Peak Capital's Pacira BioSciences position peaked at $442K in Q2 2015.
  • 177 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2015.

Based on Glacier Peak Capital's 13F filing for Q3 2015, filed 13 Nov 2015.